Dendreon (DNDN) Smacked on Positive Data from J&J's (JNJ) Zytiga
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Join SI Premium – FREE
Dendreon Corporation (Nasdaq: DNDN) is getting hit in early-morning action on positive prostate cancer results from Johnson & Johnson (NYSE: JNJ) rival drug Zytiga. The trial was stopped early due to positive efficacy.
Shares of Dendreon are down 10 percent.
Click here to see the full details of the release from Johnson & Johnson's Janssen R&D.
Shares of Dendreon are down 10 percent.
Click here to see the full details of the release from Johnson & Johnson's Janssen R&D.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Uber fined $966 Million in the Netherlands for automating driver suspensions - Reuters
- Samsung Plans As Much As $79 Billion In Shareholder Returns - Bloomberg
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
